Pacira | PCRX - Loan Capital


Pacira reported $367.66M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Assertio Holdings USD 39.17M 120K Sep/2025
Astellas Pharma JPY 320B 0 Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 51.08M 496K Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 37.53B 1.91B Mar/2026
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novo Nordisk DKK 119.17B 231M Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
Xeris Pharmaceuticals USD 221.22M 889K Mar/2026
Xoma USD 94.38M 7.82M Sep/2025
Zoetis USD 9.04B 3M Mar/2026